News

US initiative targets $200M to accelerate therapeutic cancer vaccines

The National Cancer Institute and Foundation for the NIH are seeking $200 million to support clinical trials, develop new vaccine platforms, and build a shared data resource.
Written byBree Foster, PhD
| 3 min read
Medical person holding a bottle labeled as vaccine cancer.

US partnership aims to turn cancer vaccine promise into clinical evidence.

credit: istock.com/bymuratdeniz

Register for free to listen to this article
Listen with Speechify
0:00
3:00

On November 11th, data from the INTerpath-001 Phase 3 trial provided the first clinical evidence that a personalized mRNA cancer vaccine can improve outcomes when combined with immunotherapy. The encouraging results have prompted a new US public–private initiative to accelerate the development of therapeutic cancer vaccines across multiple tumor types.

The National Cancer Institute (NCI) and the Foundation for the National Institutes of Health (FNIH) are establishing a $200 million Therapeutic Cancer Vaccines Initiative (TCVI) to advance promising vaccine candidates into clinical testing.

We're going to specifically aim for contexts where commercial interests are not already working.

—Anthony Letai, National Cancer Institute

"We're going to specifically aim for contexts where commercial interests are not already working. That is to say, we don't want to replicate work that others are doing,” said Anthony Letai, the Director of the National Cancer Institute, in the FNIH webinar hosted on November 17th.

In the INTerpath-001 trial, 1,137 patients who had undergone surgery to remove their melanoma received either Merck and Moderna’s intismeran autogene alongside the immunotherapy pembrolizumab, or pembrolizumab alone. At two years, the recurrence-free survival rate was 82.2 percent among patients who received the vaccine alongside pembrolizumab, compared with 70 percent among those who received pembrolizumab alone. The combination also improved distant metastasis-free survival, with rates of 88.5 percent and 80.2 percent, respectively.

Continue reading below...
A 3D illustration of two sphericaA 3D illustration of two spherical cells in close contact, with glowing blue nuclei and additional out-of-focus cells in the background.l cells in close contact, with glowing blue nuclei and additional out-of-focus cells in the background.
Application NoteRevealing cell-cell interactions in immuno-oncology
Imaging-enabled flow cytometry helps distinguish biologically relevant cell-cell interactions from coincident events to support immunotherapy research.
Read More

“[The trial provides] the first evidence that a modern cancer vaccine can delay cancer relapse,” said Vinod Balachandran, Founding Director of The Olayan Center for Cancer Vaccines at Memorial Sloan Kettering Cancer Center, in the FNIH webinar.

Expanding cancer vaccine research

Therapeutic cancer vaccines aim to train the immune system to recognize and attack cancer cells, including residual disease that may remain following surgery or other initial treatment. Unlike preventive vaccines, which protect against infections, these treatments are designed for people who already have the disease.

One of the central challenges is identifying antigens that distinguish cancer cells from healthy tissue. Because tumors arise from the body's own cells, the immune system does not necessarily recognize them as foreign. However, mutations acquired as cancer cells divide can produce abnormal proteins called neoantigens, which may provide targets for a tumor-specific immune response.

Intismeran is designed to exploit these differences. To tailor it to each patient, researchers analyze tumor and blood samples to identify mutations unique to an individual's cancer, selecting up to 34 neoantigens predicted to generate an immune response. The selected sequences are encoded into mRNA and packaged into lipid nanoparticles, creating a personalized vaccine intended to stimulate new T-cell responses and expand existing ones against the patient's tumor.

While the melanoma results demonstrate the potential of this approach, the NCI and FNIH want to investigate whether different vaccine platforms can generate similar benefits in other cancers.

The initiative's initial clinical program is expected to focus on pancreatic, colorectal, and liver cancers in the adjuvant setting, as well as pancreatic, colorectal, and ovarian cancers in the neoadjuvant setting. A further basket trial will investigate fusion-positive sarcomas in children and young adults.

The first two vaccine platforms selected for investigation are personalized mRNA vaccines and shared-antigen DNA vaccines. The latter target antigens found across multiple patients, potentially offering a more readily scalable alternative to manufacturing an individual vaccine for every patient.

A national learning ecosystem

The TCVI aims to establish a coordinated research infrastructure through which different vaccine approaches can be tested and compared. "I do want to emphasize that what the Therapeutic Cancer Vaccine Initiative will be building is a national learning ecosystem. We will not be backing a single product,” said Stacey Adam, Senior Vice President and Chief Clinical Officer at the FNIH, in the webinar.

The initiative will bring together vaccine manufacturers, diagnostic developers, contract research organizations, academic researchers, and patient organizations. It also plans to build on the NCI's existing clinical trial data infrastructure, creating a resource where researchers can combine clinical and biological data to investigate why particular vaccines succeed or fail.

Continue reading below...
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
ArticlesMiniaturizing patient-derived organoid screening for precision oncology
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Read More

What we hope to create is an unparalleled data resource to help us better understand the immune system and how the immune system can fight cancer in every patient.

—Stacey Adam, Foundation for the National Institutes of Health

"What we hope to create is an unparalleled data resource to help us better understand the immune system and how the immune system can fight cancer in every patient,” Adam said.

By embedding immune monitoring and data analysis into clinical trials, the partners hope to use findings from each study to inform subsequent vaccine design, antigen selection, and patient stratification.

The initiative is organized in two stages. The first three years will focus on establishing the infrastructure and conducting early demonstration studies, with a second stage intended to expand successful approaches through larger trials and broader clinical networks.

"If successful, we hope to create a phase two that we can then spread what we've learned, take the winners out of this initial effort, and put them in many centers across the country to increase access,” said Letai.

Ultimately, the partners hope to turn isolated clinical successes into a more systematic approach to cancer vaccine development, expanding access to treatments while establishing which platforms and targets offer the greatest potential across different tumor types.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • Photo of Bree Foster

    Bree Foster is a science writer at Drug Discovery News with over 5 years of experience at Technology Networks, Drug Discovery News, and other scientific marketing agencies. She holds a PhD in comparative and functional genomics from the University of Liverpool and enjoys crafting compelling stories for science. She is particularly drawn to topics around women's health, the microbiome, psychiatry, and the growing use of computational methods in drug discovery and clinical development. 

    View Full Profile

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist in protective laboratory attire examines a sample under a microscope, surrounded by digital overlays of DNA strands, molecular structures, scientific symbols, and data graphics.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
A scientist in protective laboratory attire examines a sample under a microscope, surrounded by digital overlays of DNA strands, molecular structures, scientific symbols, and data graphics.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
Blue microscopic illustration of spherical cells with textured surfaces against a dark background.
Explore how longitudinal single-cell profiling of whole blood can reveal immune signatures associated with CAR T cell therapy-related neurotoxicity.